159 related articles for article (PubMed ID: 8730550)
1. Immunophenotyping of AML and MDS and detection of residual disease.
Sanz MA; Sempere A
Baillieres Clin Haematol; 1996 Mar; 9(1):35-55. PubMed ID: 8730550
[TBL] [Abstract][Full Text] [Related]
2. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
3. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
4. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
San-Miguel JF; Vidriales MB; Orfão A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):105-18. PubMed ID: 11987919
[TBL] [Abstract][Full Text] [Related]
5. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
Zelezníková T; Babusíková O
Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
[TBL] [Abstract][Full Text] [Related]
6. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
[TBL] [Abstract][Full Text] [Related]
7. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
[TBL] [Abstract][Full Text] [Related]
9. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
[TBL] [Abstract][Full Text] [Related]
12. Correlation of morphological FAB classification and immunophenotyping: value in recognition of morphological, cytochemical and immunological characteristics of mixed leukaemias.
Boban D; Sucić M; Marković-Glamocak M; Uzarević B; Batinić D; Marusić M; Nemet D; Labar B; Hitrec V
Eur J Cancer; 1993; 29A(8):1167-72. PubMed ID: 8518029
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia.
Nakamura K; Ogata K; An E; Dan K
Br J Haematol; 2000 Mar; 108(4):710-6. PubMed ID: 10792273
[TBL] [Abstract][Full Text] [Related]
14. Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Rosenthal NS; Farhi DC
Am J Clin Pathol; 1991 Apr; 95(4):556-60. PubMed ID: 2014782
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.
Macedo A; San Miguel JF; Vidriales MB; López-Berges MC; García-Marcos MA; Gonzalez M; Landolfi C; Orfão A
J Clin Pathol; 1996 Jan; 49(1):15-8. PubMed ID: 8666678
[TBL] [Abstract][Full Text] [Related]
16. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
17. [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients].
Polák J; Marková J; Schwarz J; Maaloufová J; Volková Z; Cermák J; Haskovec C
Cas Lek Cesk; 2006; 145(1):36-42. PubMed ID: 16468240
[TBL] [Abstract][Full Text] [Related]
18. Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes.
Castoldi G; Cuneo A
Baillieres Clin Haematol; 1996 Mar; 9(1):19-33. PubMed ID: 8730549
[TBL] [Abstract][Full Text] [Related]
19. Lymphoid-associated antigen expression by acute myeloid leukemia.
Launder TM; Bray RA; Stempora L; Chenggis ML; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):185-91. PubMed ID: 8712171
[TBL] [Abstract][Full Text] [Related]
20. Light scatter characteristics of blast cells in acute myeloid leukaemia: association with morphology and immunophenotype.
Vidriales MB; Orfao A; López-Berges MC; González M; López-Macedo A; García MA; Galende J; San Miguel JF
J Clin Pathol; 1995 May; 48(5):456-62. PubMed ID: 7629293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
